Zydus Launches India's First Once-Daily Nebulised LAMA for COPD

On 11 August 2026, Zydus Lifesciences announced the REVAHALE, a once-daily nebulised long-acting muscarinic antagonist for the maintenance treatment of COPD in India. For individuals who might have trouble with traditional inhaler-based medicines, the medication offers a long-acting respiratory treatment administered using a nebuliser. The announcement demonstrates Zydus Lifesciences' ongoing commitment to increasing respiratory healthcare treatment alternatives.

Breathlessness, frequent coughing, and wheezing are signs of COPD, a chronic respiratory disease that restricts airflow via the lungs. Medications that preserve airway openness and manage respiratory symptoms are a crucial component of treatment since COPD typically necessitates continuous care. Depending on each patient's condition and capabilities, different delivery techniques can be needed.

Referencing a long-acting bronchodilator found in REVAHALE helps to enhance airflow by working on the airways. The product is administered using a nebuliser which transforms the medication into a fine mist that can be inhaled, as opposed to traditional inhaler-based delivery. This strategy may be especially helpful for people who struggle with coordination or inhaler techniques.

The product launch also underscores the pharmaceutical industry's growing emphasis on enhancing medication administration. Convenient and suitable delivery methods can be crucial in promoting consistent therapy for chronic illnesses that need ongoing care.

Impact on Healthcare Industry

By increasing the variety of respiratory medications available to patients, REVAHALÉ's introduction may benefit the pharmaceutical and healthcare sectors. The medicine offers an option for maintenance therapy for COPD by combining a long-acting mechanism with nebulised delivery.

The development of medications that can offer long-term symptom control while addressing the practical challenges patients may have during therapy is a growing emphasis in the respiratory therapies industry. By increasing treatment options across various drug delivery modalities, medical providers can choose therapies that better suit the needs of certain patients.

Patients who have trouble using inhalers or accurately performing the inhaling method may benefit from nebulised medications. Some older patients and people with more severe respiratory conditions may fall under this category. Nebulisation of a long-acting medication can therefore increase the therapy flexibility of COPD. 

The advancement also emphasises how crucial drug delivery technologies are becoming pharmaceutical innovation. Product development is increasingly taking into account a medication delivery system in addition to its therapeutic function.

The introduction might spur more innovation in respiratory treatments, especially in the creation of long-acting formulas and patient-friendly administration methods. A more varied and flexible respiratory healthcare environment may result from these advancements.

Impact on the COPD Treatment Market

The global chronic obstructive pulmonary disease (COPD) treatment market size is expected to be valued at USD 21.04 billion in 2025 and is anticipated to reach around USD 34.59 billion by 2035, expanding at a CAGR of 5.1% over the forecast period from 2026 to 2035.

By providing an additional long-acting bronchodilator option for maintenance therapy, REVAHALE entry may boost the market for COPD treatments. Precedence research states that the growing prevalence of respiratory illness, advancements in treatment technology, increased awareness of the condition, and ongoing pharmaceutical innovation are all driving the COPD treatment industry.

Depending on the patients' needs and the severity of the condition, several medications are used to treat COPD. Because bronchodilators assist in relaxing airway muscles and promote airflow, they are a crucial part of long-term treatment because their effects can last for a long time. Long-acting medications are very important for maintenance therapy.

By combining nebulised delivery with long-acting bronchodilation, REVAHALE offers an additional therapy alternative. Patients who need maintenance medication yet struggle to utilise some inhaler devices may find this helpful.

The market for COPD treatments is also being impacted by the growing development of alternative respiratory medication delivery techniques. When a patient is not a good candidate for traditional inhalation devices, nebulisation offers an alternative method of administering medications straight to the respiratory systems.

Thus, more treatment flexibility may be facilitated by the provision of once-daily nebulised therapy. It also shows how the industry is moving toward creating respiratory medications that take ease of administration and therapeutic needs into account.

Impact on the Nebulizer Market

The global nebulizer market size accounted for USD 2.17 billion in 2025 and is anticipated to hit around USD 2.31 billion by 2026 and is predicted to reach around USD 3.93 billion by 2035, growing at a CAGR of 6.12% from 2026 to 2035.

The REVAHALE is designed exclusively for nebulised administration; its debut is tightly linked to the nebuliser industry. Nebulisers are a well-known delivery system for respiratory medications because they transform liquid medication into a tiny aerosol that can be inhaled into the lungs.

According to Precedence Research, the rising incidence of respiratory disorders, the expanding use of at-home respiratory therapy and advancements in aerosol drug delivery technology all contribute to the demand for nebulisers. Nebulisers are becoming more practical and convenient for many therapeutic settings thanks to advancements in device design.

Nebulisers may play a larger role in maintenance of respiratory treatment if a long-acting medication designed for once-daily nebulisation becomes available. Although nebulisers have historically been utilized for various respiratory treatment needs, their use in routine illness management can be supported by the availability of other long-acting medications.

Additionally, the development shows how closely pharmaceuticals and medical devices are related. To ensure proper drug administration for nebulised therapies, the medication and delivery system must cooperate.

Nebulised respiratory treatments may become even more important as home-based healthcare gains popularity. Treatment strategies that can be included in everyday care routines under medical supervision may be beneficial for patients managing chronic respiratory diseases.

As a result, the launch might promote further advancements in nebuliser technology, including enhancements to patient comfort, treatment effectiveness, mobility and use.

About Zydus Lifesciences

Pharmaceutical research, development, production and commercialization are the activities of Zydus Lifescience, a multinational healthcare and life sciences corporation. In addition to operating in worldwide markets, the company is well known in India and engages in several healthcare sectors.

Respiratory healthcare is one of the several therapeutic categories in which the organization has established skills; its efforts in the field include the creation and marketing of medications meant to treat long-term respiratory disorders and give patients more treatment options.

REVAHALE, a once-daily nebulised LAMA for COPD maintenance treatment, is part of Zydus Lifesciences' respiratory portfolio expansion. The medicine offers patients who need ongoing respiratory therapy as an alternative by combining the long-acting bronchodilator reveling with nebulised administering methods.

The announcement is in line with the company's larger strategy of launching unique healthcare solutions that cater to therapeutic needs. Zydus is addressing both the practical difficulties that certain patients may encounter while utilizing traditional inhaler devices and the therapeutic requirements related to COPD by implementing alternate delivery methods.

Zydus Lifesciences' role in pulmonary medication administration and respiratory therapies is further strengthened by this breakthrough. The availability of various delivery systems can play a significant role in enhancing the entire treatment landscape as the management of chronic respiratory diseases increasingly emphasises tailored treatment and practical administration.